

ORIGINAL ARTICLE

Epidemiology and risk factors for bronchopulmonary dysplasia in preterm infants born at or less than 32 weeks of gestation[☆]



Andrea Sucasas Alonso^a, Sonia Pértega Díaz^b, Rebeca Sáez Soto^c,
Alejandro Avila-Alvarez^{a,c,*}

^a Unidad de Neonatología, Servicio de Pediatría, Complejo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, A Coruña, Spain

^b Unidad de Apoyo a la Investigación, Complejo Hospitalario Universitario A Coruña (CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain

^c Instituto de Investigación Biomédica A Coruña (INIBIC), SERGAS, Spain

Received 7 January 2021; accepted 2 March 2021

Available online 4 March 2022

KEYWORDS

Bronchopulmonary dysplasia;
Risk factors;
Prematurity;
Mechanical ventilation

Abstract

Objectives: To describe risk factors of bronchopulmonary dysplasia in very preterm infants in the first weeks of life.

Material and methods: Retrospective cohort study of preterm infants ≤ 32 weeks of gestational age and birth weight ≤ 1500 g. A multivariate logistic regression analysis was performed to identify independent risk factors for bronchopulmonary dysplasia in the first weeks of life.

Results: A total of 202 newborns were included in the study (mean gestational age 29.5 ± 2.1 weeks), 61.4% never received invasive mechanical ventilation. The incidence of bronchopulmonary dysplasia was 28.7%, and 10.4% of the patients were diagnosed with moderate-severe bronchopulmonary dysplasia. Bronchopulmonary dysplasia was independently associated with gestational age ($P < 0.001$; OR = 0.44 (95% CI = 0.30–0.65)), the need for mechanical ventilation on the first day of life ($P = 0.001$; OR = 8.13 ((95% CI = 2.41–27.42)), nosocomial sepsis ($P < 0.001$; OR = 9.51 ((95% CI = 2.99–30.28)) and FiO_2 on day 14 ($P < 0.001$; OR = 1.39 ((95% CI = 1.16–1.66))). Receiving mechanical ventilation at the first day of life ($P = 0.008$; OR = 5.39 ((95% CI = 1.54–18.89)) and at the third day of life ($P = 0.001$; OR = 9.99 ((95% CI = 2.47–40.44)) and nosocomial sepsis ($P = 0.001$; OR = 9.87 ((95% CI = 2.58–37.80))) were independent risk factors for moderate-severe bronchopulmonary dysplasia.

[☆] Please cite this article as: Sucasas Alonso A, Pértega Díaz S, Sáez Soto R, Avila-Alvarez A. Epidemiología y factores de riesgo asociados a displasia broncopulmonar en prematuros menores de 32 semanas de edad gestacional. An Pediatría. 2022;96:242–251.

* Corresponding author.

E-mail address: alejandro.avila.neonatologia@gmail.com (A. Avila-Alvarez).

Conclusions: Gestational age, mechanical ventilation in the first days of life and nosocomial sepsis are early risk factors for bronchopulmonary dysplasia. The analysis of simple and objective clinical data, allows us to select a group of patients at high risk of bronchopulmonary dysplasia in whom it could be justified to act more aggressively, and shows areas for improvement to prevent its development or reduce its severity.

© 2022 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Displasia
broncopulmonar;
Factores de riesgo;
Prematuridad;
Ventilación mecánica

Epidemiología y factores de riesgo asociados a displasia broncopulmonar en prematuros menores de 32 semanas de edad gestacional

Resumen

Objetivos: Describir los factores de riesgo de displasia broncopulmonar en las primeras semanas de vida en recién nacidos muy prematuros.

Material y métodos: Estudio observacional de cohortes retrospectivo en recién nacidos ≤ 32 semanas y ≤ 1500 gramos. Se realizó un análisis multivariante de regresión logística para identificar factores de riesgo independientes en las primeras semanas de vida.

Resultados: Se incluyeron 202 recién nacidos con una edad gestacional media de $29,5 \pm 2,1$ semanas. El 61,4% de los pacientes no recibió ventilación mecánica invasiva. El 28,7% fue diagnosticado de displasia broncopulmonar, y el 10,4% de displasia broncopulmonar moderada-grave. La edad gestacional ($p < 0,001$; OR = 0,44 (95%IC = 0,30–0,65)), la ventilación mecánica en el día 1 ($p = 0,001$; OR = 8,13 (95%IC = 2,41–27,42)), la sepsis nosocomial ($p < 0,001$; OR = 9,51 (95%IC = 2,99–30,28)) y la FiO₂ en el día 14 ($p < 0,001$; OR = 1,39 (95%IC = 1,16–1,66)) fueron los factores de riesgo independientes de displasia broncopulmonar. La ventilación mecánica el día 1 ($p = 0,008$; OR = 5,39 (95%IC = 1,54–18,89)) y 3 de vida ($p = 0,001$; OR = 9,99 (95%IC = 2,47–40,44)) y la sepsis nosocomial ($p = 0,001$; OR = 9,87 (95%IC = 2,58–37,80)) se asociaron al desarrollo de displasia broncopulmonar moderada-grave.

Conclusiones: La edad gestacional, la ventilación mecánica en los primeros días de vida y la sepsis nosocomial son factores de riesgo precoces de displasia broncopulmonar. El análisis de datos clínicos sencillos y objetivos nos permite seleccionar a un grupo de pacientes con alto riesgo de desarrollar displasia broncopulmonar en el que podría estar justificado actuar de forma más agresiva, y nos muestra áreas de mejora para prevenir su desarrollo o disminuir su gravedad.

© 2022 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Bronchopulmonary dysplasia (BPD) is a chronic pulmonary disease that affects approximately 50% of preterm neonates delivered before 28 weeks of gestation and 30% of those delivered before 32 weeks.^{1,2} The mortality is higher in infants that develop BPD,³ and those that survive are at increased risk of pulmonary and cardiovascular disease and, above all, neurodevelopmental sequelae, all of which are associated with a poorer quality of life and an increased use of health care resources.^{4–6}

The pathophysiology of BPD is multifactorial and has yet to be fully elucidated.⁷ At its core is preterm birth,⁸ on which various prenatal and postnatal factors act to modulate the baseline probability of developing the disease.⁹ Although multiple therapies have been investigated to prevent or treat BPD, a safe and effective treatment is not yet available, and evidence is mounting that there is a window of opportunity for treatment that far predates the clinical

diagnosis of BPD.¹⁰ Higgins et al.⁹ proposed that strategies aimed at preventing BPD should be implemented prenatally or in the first days post birth, mainly around the first week of life. Such interventions have been found to contribute to reducing neonatal mortality and some complications associated with prematurity.^{11,12} However, they have not resulted in a significant reduction in the incidence of BPD. The increased survival of extremely preterm infants, in whom BPD is more prevalent, could partly explain these results, but they also reflect our inability to prevent the development of BPD.^{13,14}

Thus, identifying neonates at higher risk of BPD is one of the present challenges for neonatology and has been subject to multiple studies¹⁵ with 2 main aims. The first, at the clinical level, is to enable the identification of patients in whom the benefits of currently available treatments outweigh their risks.¹⁶ The second, at the level of research, is to allow the adequate selection of candidates for new treatments in the context of clinical trials.

The aim of our study was to establish the incidence, clinical characteristics and risk factors of cases of BPD and moderate-to-severe BPD in a contemporary sample of very preterm infants, analysing prenatal variables and neonatal outcomes in the first weeks post birth.

Material and methods

Study design and sample

We conducted a retrospective observational cohort study in the level III neonatal intensive care unit (NICU) of a public hospital in Spain. We included infants born preterm at or before 32 weeks of gestation with birthweights of 1500 g or less in this hospital and admitted to the NICU between January 1, 2013 and August 30, 2020. We excluded infants with major congenital malformations or deceased before 28 days post birth. After applying the inclusion and exclusion criteria, we obtained a sample of 202 patients, which was large enough to estimate the incidence of BPD with a confidence of 95% and a precision of $\pm 6.5\%$, and to detect statistically significant relative risk (RR) values of 1.65 or greater associated with a risk factor expected in 50% of the population with a confidence of 95% and a statistical power of 80%. The protocol of the study was approved by the competent research ethics committee before its initiation.

Variables and definitions

We collected data on demographic, prenatal and obstetric characteristics, resuscitation in the delivery room and respiratory support in the first 2 weeks post birth (days 1, 3, 7 and 14), and the main outcomes associated with prematurity. The primary outcomes were BPD and moderate-severe BPD. We defined BPD as the need of supplemental oxygen at 28 days post birth (based on the nationwide SEN1500 database in Spain) and classified its severity based on oxygen requirements and need of respiratory support at 36 weeks: mild if the infant no longer required oxygen, moderate if the infant required a fraction of inspired oxygen (FiO_2) of less than 30% and severe if the infant required a FiO_2 of 30% or greater or invasive mechanical ventilation (IMV).¹⁷ We defined necrotising enterocolitis (NEC) as meeting the criteria for Bell stage 2 or higher.¹⁸ Patent ductus arteriosus (PDA) was diagnosed by means of echocardiography, ordered based on the judgment of the clinician, and treated per the unit protocol. We defined intraventricular haemorrhage (IVH) based on the grading system proposed by Volpe.¹⁹ All infants underwent screening for retinopathy or prematurity (ROP), which was graded based on Spanish guidelines.²⁰ We defined intrauterine growth restriction (IUGR) as a birth weight z-score of less than -1.5 based on the Fenton growth charts.²¹ The diagnosis of nosocomial sepsis was based on a positive result of blood culture. Metabolic bone disease of prematurity was diagnosed based on the serum levels of inorganic phosphate and alkaline phosphatase on week 3 post birth.²²

Respiratory management protocol

There were no relevant changes in respiratory management during the period under study. Resuscitation in the delivery room adhered to the recommendations of the working group on resuscitation of the Sociedad Española de Neonatología (Spanish Society of Neonatology), with initiation of respiratory support with non-invasive ventilation (NIV) with continuous positive airway pressure/non-invasive positive pressure ventilation (CPAP/NIPPV) with a T-piece resuscitator and mask.^{23,24} In the NICU, NIPPV was used for early rescue before contemplating orotracheal intubation (OTI) in the case of unfavourable progression of hyaline membrane disease. Surfactant was administered in the first hours post birth if oxygen requirements in NIV exceeded 30% or the patient required OTI. The method of choice for surfactant delivery in infants that were not intubated was the Intubation-SURfactant-Extubation (INSURE) procedure, during which NIV was maintained, avoiding the use of intermittent positive pressure breathing through the endotracheal tube, and following premedication with caffeine, fentanyl and atropine. Caffeine was administered for prophylaxis to all neonates born before 28 weeks of gestation and neonates delivered before 32 weeks if they developed apnoea of prematurity. Administration of a 22-day course of hydrocortisone (total dose 72.5 mg/kg) was contemplated in the case of intubated infants requiring a FiO_2 greater than 30% in week 3 post birth.²⁵ Two patients received experimental intravenous mesenchymal stem cell therapy in the framework of a clinical trial.

Statistical analysis

We performed a descriptive analysis, summarising quantitative variables as mean \pm standard deviation and qualitative variables as absolute frequency and percentage distributions. We used the applicable tests in the univariate analysis: Student *t* or Mann-Whitney *U* test for quantitative data and χ^2 or Fisher exact test for qualitative data. We considered *p*-values of less than 0.05 statistically significant. We performed a multivariate analysis by means of logistic to identify risk factors for BPD. In this analysis, we included variables relating to the period before the diagnosis of BPD that were statistically significant in the univariate analysis as well as variables that were not statistically significant but that we considered clinically relevant. We excluded variables that were highly correlated to one another. We generated receiver operating characteristic (ROC) curves with calculation of the area under the curve (AUC) for the final models and applied 2 predictive models for BPD previously described in the literature to our study sample^{26,27} for comparison. All the statistical analyses were made with the software SPSS version 24 (IBM Corp, Armonk, NY, USA).

Results

In the period under study, a total of 241 neonates born preterm at or before 32 weeks of gestation with a birthweight of 1500 g or less. We excluded those with major congenital malformations ($n = 16$) and those deceased before 28 days post birth, in who it was not possible




Figure 1 Flowchart of the study sample. BPD, bronchopulmonary dysplasia; NICU, neonatal intensive care unit.

to diagnose BPD ($n = 23$, of who 8 died from respiratory causes). The final sample included 202 very preterm infants (106 female, 52.5%) (Fig. 1). The mean gestational age was 29.5 ± 2.1 weeks and the mean birthweight 1142.1 ± 255.5 g. Table 1 presents the main perinatal characteristics of the sample and the most relevant neonatal diagnosis and outcomes.

A total of 58 patients (28.7%) received a diagnosis of BPD, of who 21 (10.4% of the total) were classified as cases of moderate-severe BPD; Fig. 2 presents the distribution of cases by weeks of gestational age. Forty neonates (19.8%) required intubation in the delivery room, and 101 (50%) required surfactant during the stay. Seventy-eight (38.6%) received IMV during the stay, and the rest of the patients ($n = 124$) only required non-invasive respiratory support. None of the patients died after 28 days post birth.

Table 2 summarises the results of the univariate analysis for BPD. The most relevant independent risk factors for BPD identified in the logistic regression analysis were gestational age (odds ratio [OR], 0.44; 95% CI = 0.30–0.65; $P < 0.001$),

the need of IMV in the first day post birth (OR, 8.13; 95% CI = 2.41–27.42; $P = 0.001$), nosocomial sepsis (OR, 9.51; 95% CI = 2.99–30.28; $P < 0.001$) and the FiO_2 on day 14 post birth (OR, 1.39; 95% CI = 1.16–1.66; $P < 0.001$) (Fig. 3). The AUC for the BPD model was 0.967 (95% CI, 0.944–0.990).

Table 3 summarises the results of the univariate analysis for moderate-to-severe BPD. The most relevant independent risk factors for moderate-severe BPD identified in the logistic regression analysis were the need of IMV on days 1 (OR, 5.39; 95% CI = 1.54–18.89; $P = 0.008$) and 3 of life (OR, 9.99; 95% CI = 2.47–40.44; $P = 0.001$) and diagnosis of nosocomial sepsis (OR, 9.87; 95% CI = 2.58–37.80; $P = 0.001$) (Fig. 3). The AUC for the moderate-severe BPD model was 0.891 (95% CI, 0.812–0.971).

The AUCs for the ROC curves of the previously published models selected for comparison were smaller compared to the AUCs obtained in our models. In the case of Gursoy et al.,²⁷ the model for prediction of BPD had an AUC of 0.869 (95% CI, 0.815–0.922) and the model for moderate-severe BPD an AUC of 0.803 (95% CI, 0.711–0.895). In the case of Hunt et al.,²⁶ the model for prediction of BPD had an AUC of 0.600 (95% CI, 0.508–0.692) and the model for moderate-severe BPD an AUC of 0.624 (95% CI, 0.480–0.767).

Discussion

A better understanding of the risk factors for BPD is a key step toward the prevention and adequate management of this disease. Our study, conducted in a consecutive sample of infants delivered at or before 32 weeks of gestation with birthweights of 1500 g or less, most of who were managed with non-invasive support, and with an incidence of BPD similar to the incidence described in the previous literature, corroborated that lesser GA, the need of IMV in the first days post birth and nosocomial infection are the main early risk factors for BPD. The predictive ability of our models improved compared to past models.^{26,27}

In our patients, the incidence of moderate-severe BPD was 10.4%, lower compared to the national mean (15.8%) based on data from the SEN1500 study published by the iNeo network,¹¹ which reported a significantly higher global incidence for participating countries (25.5%). These improved outcomes were also reflected in the survival free of moderate-severe BPD in infants delivered at or before 28 weeks, which was of 79.2% in our sample, greater than the national mean (61.4%), but similar to survival in hospitals in our region that have reported more favourable outcomes (72.5%).²⁸ A factor that may play a role in these results is the lower frequency of extremely preterm infants in our case series.

It is widely accepted that gestational age is the best isolated predictor of BPD,⁷ although in most instances this is not a modifiable factor. At birth, the respiratory prognosis is often influenced by the cause of preterm birth and by the resulting interruption of foetal lung maturation.^{7,9} Thus, gestational birth is a very important factor in the most premature infants, who are born at a very early stage of lung maturation.⁷ It is highly probable that these infants will develop BPD independently of how they are managed after birth.⁹ Notwithstanding, there are multiple postnatal factors that can play a role in the severity of BPD and

Table 1 Descriptive analysis of study sample.

Perinatal characteristics, mean \pm SD	Total sample $n = 202$	GA ≤ 28 wk, $n = 77$	GA 29–32 wk, $n = 125$
Gestational age (weeks)	29.50 \pm 2.1	27.3 \pm 1.2	30.8 \pm 1.1
Birthweight (g)	1142.08 \pm 255.5	956.52 \pm 218.5	1250.84 \pm 212.8
Weight z-score	-0.46 \pm 0.8	-0.01 \pm 0.8	-0.74 \pm 0.6
Maternal age (years)	34.19 \pm 6.3	33.8 \pm 6.6	34.4 \pm 6.2
<i>n</i> (%)			
Maternal HTN	46 (22.8%)	13 (16.9%)	33 (26.4%)
Chorioamnionitis	32 (15.8%)	21 (27.3%)	11 (8.8%)
Antenatal steroids ^a	198 (98%)	77 (100%)	121 (96.8%)
Multiple birth	77 (38.1%)	22 (28.6%)	55 (44%)
Vaginal delivery	46 (22.8%)	20 (26%)	26 (20.8%)
IVF	51 (25.2%)	15 (19.5%)	36 (28.8%)
Sex (female)	106 (52.5%)	44 (57.1%)	62 (49.6%)
IUGR	18 (8.9%)	3 (3.9%)	15 (12%)
Neonatal outcomes mean \pm SD			
Length of stay, NICU	26.39 \pm 18.9	41.29 \pm 19.1	17.2 \pm 11.5
Length of stay, total	61.14 \pm 55.6	85.8 \pm 82.5	45.83 \pm 14.2
<i>n</i> (%)			
BPD	58 (28.7%)	50 (64.9%)	8 (6.4%)
moderate-severe BPD	21 (10.4%)	17 (22.1%)	4 (3.2%)
Oxygen at discharge	8 (4%)	6 (7.8%)	2 (1.6%)
PDA	41 (20.3%)	31 (40.3%)	10 (8%)
Pharmacological closure of PDA	29 (14.4%)	24 (31.2%)	5 (4%)
Surgical closure of PDA	12 (5.9%)	9 (11.7%)	3 (2.4%)
NEC	11 (5.4%)	7 (9.1%)	4 (3.2%)
ROP grade > II	22 (10.9%)	20 (26.3%)	14 (11.2%)
Nosocomial sepsis	73 (36.1%)	41 (53.2%)	32 (25.6%)
IVH grade > II	12 (5.9%)	11 (14.3%)	1 (0.8%)
PVL	13 (6.4%)	10 (13%)	3 (2.4%)
MBD	42 (20.8%)	21 (27.3%)	21 (16.8%)

AUC, area under the curve; BPD, bronchopulmonary dysplasia; GA, gestational age; HTN, hypertension; IQR, interquartile range; IUGR, intrauterine growth restriction; IVF, in vitro fertilization; IVH, intraventricular haemorrhage; MBD, metabolic bone disease; NEC, necrotising enterocolitis; NICU, neonatal intensive care unit; PDA, patent ductus arteriosus; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity; SD, standard deviation; wk, week.

^a Antenatal steroids: counts patients that received a full course for lung maturation.

therefore influence its outcomes, especially in less preterm infants. The activation of the inflammatory cascade and oxidative stress are 2 of the key pathophysiological pathways leading to the development of BPD. In association with this physiological basis, factors such as positive airway pressure, supplemental oxygen and postnatal sepsis have also been found to be related to BPD,⁷ as occurred in our study.

Several studies have described patterns of disease that can usually be identified in the first weeks of life.^{29,30} First, there are infants with mild pulmonary disease at birth that recover gradually. Then, there are infants that experience early persistent pulmonary deterioration and usually require prolonged respiratory support starting from birth. Lastly, there are infants who recover from initial lung disease but later experience respiratory decompensation.⁷ This goes beyond what Northway described in 1967 in patients with BPD, then defined as the pulmonary disease developed by preterm infants subjected to prolonged mechanical

ventilation.³¹ Today's preterm infants do not have the same characteristics and are managed differently compared to the population in which BPD was first defined. Strategies used to improve lung development outcomes (used of synchronised ventilation modalities, standardization of lung volumes, increased use of NIV, early administration of surfactant and antenatal steroids) have resulted in the different population of patients we manage today.²⁹ Every infant in our study was managed with these methods, as we obtained a consecutive sample of infants managed in the past decade. Thus, fewer than 4 in 10 patients received IMV during the hospital stay, and fewer than 2 in 10 required endotracheal intubation at birth. Notwithstanding, there is still a group of patients in whom the need of intubation and of IMV cannot be avoided.

When we analysed the relationship between IMV and BPD in the sample, we found that the need of IMV in the first days post birth was independently associated with the development of BPD, as previously described.^{32,33} Sixty percent




Figure 2 Bar graph of the distribution of patients by weeks of gestational age at birth and number of patients with BPD and moderate-severe BPD in each age group. BPD, bronchopulmonary dysplasia.

of the patients that required intubation during stabilization in the delivery room developed BPD, and the percentage increased to 70% in those who required IMV in the first day of life. In contrast, only 14% of patients that were not intubated in the first day of life developed BPD. Similarly, nearly 9 out of 10 patients that needed IMV on day 3 post birth developed BPD and more than 50% moderate-severe BPD.

Our findings evinced another opportunity for improvement in the use of NIV for initial respiratory support. In our sample of very and extremely preterm infants, 8 in 10 received non-invasive respiratory support in the delivery room. In the group of patients that developed BPD, 60% had received CPAP/NIPPV at birth. However, this proportion decreased to 40% in the first 24 h post birth. Thus, there was a sizeable group of patients in who NIV failed in the first hours post birth and who eventually developed BPD. This was consistent with the findings in other case series in which CPAP failure was associated with an increase in morbidity, including BPD.³⁴ Thorough investigation of these cases to establish NIV protocols and improve the respiratory management of these patients is an essential step that could help avoid IMV in a particularly important stage of disease development.^{33,35,36}

Multiple previous studies have demonstrated the association between postnatal sepsis and the development of pulmonary inflammation.^{37–39} Some have found evidence suggestive of a causal relationship between postnatal infection, PDA and increased duration of IMV.^{37,39} All these factors are probably interrelated. However, in our study nosocomial sepsis remained an independent risk factor in the final logistic regression model. In fact, its presence was associated with a more than 9-fold increase in the risk of BPD as well as with the severity of BPD. Thus, in our population, nosocomial sepsis should be considered a risk factor in

and of its own. Improving the rate of nosocomial infection through stricter protocols and limited use of invasive procedures is another of the preventive strategies that should be prioritised.

There are limitations to our study, including its retrospective design, performance in a single centre and small sample size, in addition to the inclusion of preterm infants born between 28 and 32 weeks of gestation, in who the baseline risk of BPD is low. The definition of BPD as oxygen dependence at 28 days post birth also carries intrinsic limitations, such as the discrepancy with the criterion established in the 2001 consensus (dependency for 28 days). This could hinder comparisons with the results of other studies. The values of the AUCs in the ROC curves of our models should be interpreted with caution, as we did not select variables for application at specific time points and we did not correct for the overestimation that may result from testing the model in the same patients from who it was derived. Our conclusions should be analysed with prudence and are only directly applicable to the population under study. On the other hand, the study was conducted in a homogeneous consecutive sample spanning 7 years during which the same protocols were applied and there were no significant changes in clinical management, which was akin to clinical practice in other facilities in our region.

In conclusion, the analysis of simple and objective data available in the first days post birth, such as GA at birth and the need of IMV in days 1 and 3 of life, can help identify a subset of patients at high risk of BPD in whom more aggressive management may be warranted. Our findings may provide the foundation to develop early-stage predictive models or to compare the predictive power of new tools using clinical data that can be obtained at the bedside.

Table 2 Risk factors for bronchopulmonary dysplasia.

	BPD (n = 58)	No BPD (n = 144)	p	AUC	95% CI
<i>Perinatal characteristics</i>					
mean ± SD					
Gestational age ^a	27.5 ± 1.7	30.3 ± 1.6	<0.001	0.888	0.77–1
Weight (g) ^b	938.7 ± 216.8	1224 ± 222.5	<0.001	0.790	0.62–0.96
Weight z-score ^b	−0.2 ± 0.9	−0.6 ± 0.8	0.005	0.628	0.54–0.72
Maternal age (years)	34.2 ± 6.9	34.2 ± 6.1	0.980	0.500	0.41–0.59
n (%)					
Maternal hypertension	12 (20.7%)	34 (23.6%)	0.654	0.885	0.51–1.52
Chorioamnionitis	10 (17.2%)	22 (15.3%)	0.729	1107	0.63–1.95
Antenatal steroids ^c	57 (98.3%)	141 (97.9%)	0.868	1515	0.21–6.37
Multiple birth	19 (32.8%)	58 (40.3%)	0.319	0.791	0.49–1.36
IVF	12 (20.7%)	39 (27.1%)	0.344	0.772	0.44–1.34
Vaginal delivery	17 (29.3%)	29 (20.1%)	0.160	1406	0.89–2.23
Female sex	27 (46.6%)	79 (54.8%)	0.285	0.789	0.51–1.22
IUGR	3 (5.2%)	15 (10.4%)	0.237	0.557	0.19–1.60
<i>Resuscitation in delivery room</i>					
n (%)					
Oxygen ^b	55 (94.8%)	114 (79.2%)	0.006	RR 3580	95% CI 1.29–10.76
OTI ^b	24 (41.4%)	16 (11.1%)	<0.001	2859	1.93–4.23
Cardiac massage	4 (6.9%)	6 (4.2%)	0.418	1422	0.64–3.14
Adrenaline	3 (5.2%)	4 (2.8%)	0.400	1519	0.63–3.68
<i>Neonatal outcomes</i>					
mean ± SD					
FiO ₂ day 1 ^b	28.9 ± 13.1	23.9 ± 5.5	0.007	AUC 0.661	95% CI 0.58–0.74
FiO ₂ day 3 ^b	26 ± 7.5	22.3 ± 3.1	0.001	0.699	0.61–0.78
FiO ₂ day 7 ^b	25.4 ± 6.2	21.7 ± 2.4	<0.001	0.709	0.62–0.80
FiO ₂ day 14 ^a	27.8 ± 7.2	21.4 ± 1.9	<0.001	0.835	0.76–0.91
n (%)					
Surfactant ^b	50 (86.2%)	51 (35.4%)	<0.001	RR 6250	95% CI 3.12–12.50
nCPAP	58 (100%)	137 (95.1%)	0.087	–	–
NIPPV ^b	57 (98.3%)	53 (36.8%)	<0.001	47,673	6.73–337.63
CMV ^b	50 (86.2%)	28 (19.4%)	<0.001	9936	1.98–19.82
HFOV ^b	5 (8.6%)	3 (2.1%)	0.031	2288	1.28–4.10
IMV day 1 post birth ^a	36 (62.1%)	15 (10.4%)	<0.001	4845	3.17–7.41
IMV day 3 post birth ^b	18 (31%)	3 (2.1%)	<0.001	3878	2.80–5.36
IMV day 7 post birth ^b	12 (20.7%)	1 (0.7%)	<0.001	3792	2.82–5.10
IMV day 14 post birth ^b	17 (29.3%)	1 (0.7%)	<0.001	4238	3.16–5.68
PDA ^b	26 (44.8%)	15 (10.4%)	<0.001	3190	2.16–4.70
Pharmacological closure of PDA ^b	20 (34.5%)	9 (6.3%)	<0.001	3140	2.16–4.55
Surgical closure of PDA ^b	9 (15.5%)	3 (2.1%)	<0.001	2908	1.94–4.36
Sepsis nosocomial ^a	41 (70.7%)	32 (22.2%)	<0.001	4262	2.62–6.94

AUC, area under the curve; CI, confidence interval; CMV, conventional mechanical ventilation; HFOV, high-frequency oscillatory ventilation; HTN, hypertension; IMV, invasive mechanical ventilation; IUGR, intrauterine growth restriction; IVF, in vitro fertilization; nCPAP, nasal continuous positive airway pressure; NIPPV, non-invasive positive pressure ventilation; OTI, orotracheal intubation; PDA, patent ductus arteriosus; RR, relative risk; SD, standard deviation.

^a Variables included as risk factors in the final logistic regression model of BPD.

^b Statistically significant association with BPD.

^c Antenatal steroids: counts patients that received a full course for lung maturation.

Table 3 Risk factors for moderate-to-severe bronchopulmonary dysplasia.

	Moderate-severe BPD (n = 21)	No moderate-severe BPD (n = 181)	p	AUC	95% CI
<i>Perinatal characteristics</i>					
mean ± SD					
Gestational age ^b	27.78 ± 2	29.7 ± 2	<0.001	0.447	0.12–0.79
Weight (g) ^b	923.1 ± 268.3	1167.5 ± 242.2	<0.001	0.404	0.10–0.70
Weight z-score	−0.5 ± 0.8	−0.4 ± 0.8	0.604	0.649	0.30–0.99
Maternal age (years)	33 ± 6.3	34.3 ± 6.3	0.365	0.429	0.30–0.56
n (%)					
Maternal HTN	6 (28.6%)	40 (22.1%)	0.503	RR 1356	95% CI 0.56–3.30
Chorioamnionitis	2 (9.5%)	30 (16.6%)	0.402	0.559	0.14–2.28
Antenatal steroids ^a	20 (95.2%)	178 (98.3%)	0.334	0.404	0.07–2.32
Multiple birth	9 (42.9%)	68 (37.6%)	0.637	1217	0.54–2.75
IVF	4 (19%)	47 (26%)	0.490	0.696	0.25–1.97
Vaginal delivery	6 (28.6%)	40 (22.1%)	0.552	1356	0.56–3.30
Sex (female)	8 (38.1%)	98 (54.1%)	0.163	0.557	0.24–1.29
IUGR	1 (4.8%)	17 (9.4%)	0.481	0.511	0.07–3.60
<i>Resuscitation in delivery room</i>					
n (%)					
Oxygen ^b	21 (100%)	148 (81.8%)	0.032	–	–
OTI ^c	8 (38.1%)	32 (17.7%)	0.026	2492	1.11–5.60
Cardiac massage	1 (4.8%)	9 (5%)	0.966	0.960	0.14–6.45
Adrenaline	0	7 (3.9%)	0.359	–	–
<i>Neonatal outcomes</i>					
mean ± SD					
FiO ₂ day 1 ^b	32.9 ± 17.2	24.5 ± 6.6	0.007	AUC 0.733	95% CI 0.61–0.85
FiO ₂ day 3 ^b	27.7 ± 8.2	22.9 ± 4.3	0.037	0.716	0.59–0.85
FiO ₂ day 7 ^b	26.6 ± 6.6	22.3 ± 3.7	0.015	0.709	0.57–0.84
FiO ₂ day 14 ^b	29.7 ± 8.1	22.5 ± 4	0.009	0.826	0.72–0.93
n (%)					
Surfactant ^b	20 (95.2%)	81 (44.8%)	<0.001	RR 20,000	95% CI 2.74–146.21
nCPAP	21 (100%)	174 (96.1%)	0.359	–	–
NIPPV ^b	21 (100%)	89 (49.2%)	0.010	–	–
CMV ^b	20 (95.2%)	58 (32%)	<0.001	31,795	4.35–232.20
HFOV ^b	3 (14.3%)	5 (2.8%)	0.010	4042	1.49–10.95
IMV day 1 post birth ^c	16 (76.2%)	36 (19.9%)	<0.001	9474	3.65–24.56
IMV day 3 post birth ^c	11 (52.4%)	10 (5.5%)	<0.001	9481	4.58–19.62
IMV day 7 post birth ^b	6 (28.6%)	7 (3.9%)	<0.001	5815	2.71–12.46
IMV day 14 post birth ^b	8 (38.1%)	10 (5.5%)	<0.001	6290	3.01–13.13
PDA ^b	10 (47.6%)	31 (17.1%)	0.001	3570	1.63–7.82
Pharmacological closure of PDA ^b	7 (33.3%)	22 (12.2%)	0.009	2983	1.32–6.76
Surgical closure of PDA ^b	5 (23.8%)	7 (3.9%)	<0.001	4948	2.18–11.20
Nosocomial sepsis	17 (81%)	56 (30.9%)	<0.001	7510	2.63–21.48

AUC, area under the curve; CI, confidence interval; CMV, conventional mechanical ventilation; HFOV, high-frequency oscillatory ventilation; HTN, hypertension; IMV, invasive mechanical ventilation; IUGR, intrauterine growth restriction; IVF, in vitro fertilization; nCPAP, nasal continuous positive airway pressure; NIPPV, non-invasive positive pressure ventilation; OTI, orotracheal intubation; PDA, patent ductus arteriosus; RR, relative risk; SD, standard deviation.

^a Antenatal steroids: counts patients that received a full course for lung maturation.

^b Statistically significant association with BPD.

^c Variables included as risk factors in the final logistic regression model of BPD.




Figure 3 Forest plot of the odd ratios obtained in the logistic regression models of bronchopulmonary dysplasia and moderate-to-severe bronchopulmonary dysplasia with the corresponding 95% confidence intervals. BPD, bronchopulmonary dysplasia; IMV, invasive mechanical ventilation.

Data availability

Data will be made available on request.

Funding

This research did not receive any external funding.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

- Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. *Birth Defects Res A Clin Mol Teratol.* 2014;100:145–57.
- García-Muñoz Rodrigo F, Losada Martínez A, Elorza Fernández MD, Moreno Hernando J, Figueras Aloy J, Vento Torres M. The burden of respiratory disease in very-low-birth-weight infants: changes in perinatal care and outcomes in a decade in Spain. *Neonatology.* 2017;112:30–9.
- De Jesus LC, Pappas A, Shankaran S, Kendrick D, Das A, Higgins RD, et al. Risk factors for post-neonatal intensive care unit discharge mortality among extremely low birth weight infants. *J Pediatr.* 2012;161:70–4.
- Fawke J, Lum S, Kirkby J, Hennessy E, Marlow N, Rowell V, et al. Lung function and respiratory symptoms at 11 years in children

born extremely preterm: the EPICure study. *Am J Respir Crit Care Med.* 2010;182:237–45.

- Cheong JLY, Doyle LW. An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia. *Semin Fetal Neonatal Med.* 2018;42:478–84.
- Álvarez-Fuente M, Arruza L, Muro M, Zozaya C, Avila A, López-Ortego P, et al. The economic impact of prematurity and bronchopulmonary dysplasia. *Eur J Pediatr.* 2017;176:1587–93.
- Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. *Nat Rev Dis Prim.* 2019;5.
- O'Reilly M, Sozo F, Harding R. Impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long-term consequences for respiratory health. *Clin Exp Pharmacol Physiol.* 2013;40:765–73.
- Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, et al. Bronchopulmonary dysplasia: executive summary of a workshop. *J Pediatr.* 2018;197:300–8.
- Leroy S, Caumette E, Waddington C, Hébert A, Brant R, Lavoie PM. A time-based analysis of inflammation in infants at risk of bronchopulmonary dysplasia. *J Pediatr.* 2018;192, 60–5.e1.
- Lui K, Lee SK, Kusuda S, Adams M, Vento M, Reichman B, et al. Trends in outcomes for neonates born very preterm and very low birth weight in 11 high-income countries. *J Pediatr.* 2019;215:32–40.
- Webbe JWH, Duffy JMN, Afonso E, Al-Muzaffar I, Brunton G, Greenough A, et al. Core outcomes in neonatology: development of a core outcome set for neonatal research. *Arch Dis Child Fetal Neonatal Ed.* 2020;105:425–31.
- Onland W, de Laat MW, Mol BW, Offringa M. Effects of antenatal corticosteroids given prior to 26 weeks' gestation: a systematic review of randomized controlled trials. *Am J Perinatol.* 2011;28:33–44.
- Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. *JAMA J Am Med Assoc.* 2011;306:2348–58.
- Onland W, Debray TP, Laughon MM, Miedema M, Cools F, Askie LM, et al. Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study. *BMC Pediatr.* 2013;13:207.
- Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. *Pediatrics.* 2005;115:655–61.
- Jobe AH, Bancalari E. NICHD/NHLBI/ORD workshop summary. *Am J Respir Crit Care Med.* 2001;163:1723–9.
- Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. *Ann Surg.* 1978;187:1–7.
- Volpe JJ. Perinatal brain injury: from pathogenesis to neuroprotection. *Ment Retard Dev Disabil Res Rev.* 2001;7:56–64.
- Castro Conde JR, Echániz Urcelay I, Botet Mussons F, Pallás Alonso CR, Narbona E, Sánchez Luna M. Comisión de Estándares de la Sociedad Española de Neonatología [Retinopathy of prematurity. Prevention, screening and treatment guidelines]. *An Pediatr.* 2009;71:514–23.
- Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatr.* 2013;13:59.
- Backström MC, Kouri T, Kusela AL, Sievänen H, Koivisto AM, Ikonen RS, et al. Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. *Acta Paediatr Int J Paediatr.* 2000;89:867–73.
- Zeballos Sarrato G, Salguero García E, Aguayo Maldonado J, Gómez Robles C, Thió Lluç M, Iriondo Sanz M. Adaptación de

- las recomendaciones internacionales en estabilización y reanimación neonatal 2015. *An Pediatría*. 2017;86, 51.e1–9.
24. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, et al. European consensus guidelines on the management of respiratory distress syndrome — 2019 update. *Neonatology*. 2019;115:432–50.
 25. Rademaker KJ, Uiterwaal CSPM, Groenendaal F, Venema MMATU, van Bel F, Beek FJ, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. *J Pediatr*. 2007;150:351–7.
 26. Hunt KA, Dassios T, Ali K, Greenough A. Prediction of bronchopulmonary dysplasia development. *Arch Dis Child Fetal Neonatal Ed*. 2018;103:F598–9.
 27. Gursoy T, Hayran M, Derin H, Ovali F. A clinical scoring system to predict the development of bronchopulmonary dysplasia. *Am J Perinatol*. 2014;32:659–65.
 28. García-Muñoz Rodrigo F, Urquía Martí L, Galán Henríquez G, Rivero Rodríguez S, Figueras-Aloy J, Vento M. Intercenter variability and factors associated with survival without bronchopulmonary dysplasia in extremely preterm newborns. *J Matern Neonatal Med*. 2020;33:3767–74.
 29. Laughon M, Bose C, Allred EN, O’Shea TM, Ehrenkranz RA, Van Marter LJ, et al. Antecedents of chronic lung disease following three patterns of early respiratory disease in preterm infants. *Arch Dis Child Fetal Neonatal Ed*. 2011;96:114–20.
 30. Nobile S, Marchionni P, Vento G, Vendettuoli V, Marabini C, Lio A, et al. New insights on early patterns of respiratory disease among extremely low gestational age newborns. *Neonatology*. 2017;112:53–9.
 31. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. *New Engl J Med*. 1967;276:357–68.
 32. Keszler M, Sant’Anna M. Mechanical ventilation and bronchopulmonary dysplasia. *Clin Perinatol*. 2015;42:781–96.
 33. Sharma A, Xin Y, Chen X, Sood BG. Early prediction of moderate to severe bronchopulmonary dysplasia in extremely premature infants. *Pediatr Neonatol [Internet]*. 2020;61:290–9.
 34. Dargaville PA, Gerber A, Johansson S, De Paoli AG, Kamlin COF, Orsini F, et al. Australian and New Zealand Neonatal Network. Incidence and outcome of CPAP failure in preterm infants. *Pediatrics*. 2016;138. PMID: 27365307.
 35. Kobaly K, Schluchter M, Minich N, Friedman H, Taylor HG, Wilson-Costello D, et al. Outcomes of extremely low birth weight (<1 kg) and extremely low gestational age (<28 weeks) infants with bronchopulmonary dysplasia: effects of practice changes in 2000 to 2003. *Pediatrics*. 2018;121:73–81.
 36. Trembath A, Laughon MM. Predictors of bronchopulmonary dysplasia. *Clin Perinatol*. 2012;39:585–601.
 37. Rojas MA, Gonzalez A, Bancalari E, Claire N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. *J Pediatr*. 1995;126:605–10.
 38. Van Marter LJ, Dammann O, Allred EN, Leviton A, Pagano M, Moore M, et al. Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. *J Pediatr*. 2002;140:171–6.
 39. Kim SH, Han YS, Chun J, Lee MH, Sung TJ. Risk factors that affect the degree of bronchopulmonary dysplasia: comparison by severity in the same gestational age. *PLoS One [Internet]*. 2020;15:1–12.